Karyopharm Therapeutics | KPTI - Ebit


Karyopharm Therapeutics reported $-26.76M in EBIT for its fiscal quarter ending in March of 2026.





Ebit Change Date
AbbVie USD 6.88B 156M Sep/2026
Abbott USD 1.36B 775M Sep/2026
Amgen USD 4.68B 65M Sep/2026
AstraZeneca USD 4.66B 1.5B Sep/2026
BioCryst Pharmaceuticals USD 98.46M 161.92M Jun/2026
Bristol-Myers Squibb USD 255M 44M Sep/2026
Eli Lilly USD 13.09B 635M Sep/2026
Enanta Pharmaceuticals USD -23.54M 6.31M Dec/2024
GlaxoSmithKline GBP 2.86B 251M Sep/2026
Incyte USD -707.47M 1.41B Sep/2026
J&J USD 6.47B 1B Sep/2026
Karyopharm Therapeutics USD -26.76M 8.92M Mar/2026
MacroGenics USD -65.25M 33.36M Jun/2026
Merck USD 7.33B 6.49B Sep/2026
Nektar Therapeutics USD -38.26M 19.17M Mar/2026
Novartis USD 5.14B 411M Sep/2026
Novartis USD 1.78B 2.4B Sep/2026
Pfizer USD 4.85B 5.03B Sep/2026
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Roche Holding CHF 11.46B 1.91B Jun/2026
Takeda JPY 205.32B 3.9B Sep/2026
Tectonic Therapeutic USD -24.22M 3.08M Jun/2026
TG Therapeutics USD 21.67M 13.12M Jun/2026
Ultragenyx Pharmaceutical USD -110M 35M Sep/2026
Xencor USD -36.6M 41.26M Jun/2026